| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Oncogen, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121
We have purified a protein from serum-free conditioned medium of the HT29 human colon adenocarcinoma cell line based on its ability to inhibit the proliferation of the same cell line. The purification procedure consisted of acid gel permeation, semipreparative, and analytical reversed-phase chromatographies. The high-pressure liquid chromatography-purified colon cancer cell growth inhibitor migrates as a single band of 27 and 34 kDa on sodium dodecyl sulfate/polyacrylamide gels under nonreducing and reducing conditions, respectively. NH2-terminal amino acid sequence analysis of the first 32 residues has demonstrated that this protein belongs to the insulin-like growth factor-binding protein (IGFBP) family. More precisely, this growth inhibitor appeared to be identical to the recently cloned human IGFBP-4. This IGFBP (HT29-IGFBP) has been characterized by performing ligand blotting and competitive binding experiments. The affinity of HT29-IGFBP for insulin-like growth factor (IGF) II (
3.4 x 1010 M-1) is slightly greater than its affinity for IGF-I (1.4 x 1010 M-1). HT29 cells also produce two other isoforms (28 and 31 kDa, nonreduced) of the HT29-IGFBP having the same partial NH2-terminal amino acid sequence as the 27-kDa protein. The monoclonal antibody 
IR-3 is known to block the mitogenic actions of IGFs. IR-3 inhibited the growth of HT29 cells, thus suggesting that IGFs are required for the growth of these colon cancer cells.
1 To whom requests for reprints should be addressed, at Oncogen, Bristol-Myers Squibb Pharmaceutical Research Institute, 3005 First Avenue, Seattle, WA 98121.
Received 12/12/90. Accepted 3/14/91.
This article has been cited by other articles:
|
|
 |
|
  Y. Ning, A. G. P. Schuller, C. A. Conover, and J. E. Pintar Insulin-Like Growth Factor (IGF) Binding Protein-4 Is Both a Positive and Negative Regulator of IGF Activity in Vivo Mol. Endocrinol., May 1, 2008; 22(5): 1213 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhao, M. Berho, J. Nogueras, D. Sands, E. Weiss, S. Wexner, F. M. Giardiello, and M. Cruz-Correa Positive Correlation of Insulin-Like Growth Factor-II with Proliferating Cell Index in Patients with Colorectal Neoplasia Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1819 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-K. Chen, M. T. Overgaard, L. K. Bale, Z. T. Resch, M. Christiansen, C. Oxvig, and C. A. Conover Molecular Regulation of the IGF-Binding Protein-4 Protease System in Human Fibroblasts: Identification of a Novel Inducible Inhibitor Endocrinology, April 1, 2002; 143(4): 1199 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. KIEPE, D. L. ANDRESS, S. MOHAN, L. STANDKER, T. ULINSKI, R. HIMMELE, O. MEHLS, and B. TONSHOFF Intact IGF-Binding Protein-4 and -5 and Their Respective Fragments Isolated from Chronic Renal Failure Serum Differentially Modulate IGF-I Actions in Cultured Growth Plate Chondrocytes J. Am. Soc. Nephrol., November 1, 2001; 12(11): 2400 - 2410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Byun, S. Mohan, C. Kim, K. Suh, M. Yoo, H. Lee, D. J. Baylink, and X. Qin Studies on Human Pregnancy-Induced Insulin-Like Growth Factor (IGF)-Binding Protein-4 Proteases in Serum: Determination of IGF-II Dependency and Localization of Cleavage Site J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 373 - 381. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Yamanaka, J. L. Fowlkes, E. M. Wilson, R. G. Rosenfeld, and Y. Oh Characterization of Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) Binding to Human Breast Cancer Cells: Kinetics of IGFBP-3 Binding and Identification of Receptor Binding Domain on the IGFBP-3 Molecule Endocrinology, March 1, 1999; 140(3): 1319 - 1328. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Qin, D. D. Strong, D. J. Baylink, and S. Mohan Structure-Function Analysis of the Human Insulin-like Growth Factor Binding Protein-4 J. Biol. Chem., September 4, 1998; 273(36): 23509 - 23516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dai, S. G. Widen, R. Mifflin, and P. Singh Cloning of the Functional Promoter for Human Insulin-Like Growth Factor Binding Protein-4 Gene: Endogenous Regulation Endocrinology, January 1, 1997; 138(1): 332 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Fowlkes, D. M. Serra, C. K. Rosenberg, and K. M. Thrailkill Insulin-like Growth Factor (IGF)-binding Protein-3 (IGFBP-3) Functions as an IGF-reversible Inhibitor of IGFBP-4 Proteolysis J. Biol. Chem., November 17, 1995; 270(46): 27481 - 27488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mohan, Y. Nakao, Y. Honda, E. Landale, U. Leser, C. Dony, K. Lang, and D. J. Baylink Studies on the Mechanisms by Which Insulin-like Growth Factor (IGF) Binding Protein-4 (IGFBP-4) and IGFBP-5 Modulate IGF Actions in Bone Cells J. Biol. Chem., September 1, 1995; 270(35): 20424 - 20431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Conover, S. K. Durham, Jür. Zapf, F. R. Masiarz, and M. C. Kiefer Cleavage Analysis of Insulin-like Growth Factor (IGF)-dependent IGF-binding Protein-4 Proteolysis and Expression of Protease-resistant IGF-binding Protein-4 Mutants J. Biol. Chem., March 3, 1995; 270(9): 4395 - 4400. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
